ADCs, Oncology Move To Fore In Korean Biopharma Alliances
Plus Pandemic-Related Production Deals
Executive Summary
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
You may also be interested in...
Deal Watch: Deal Volume On The Rise Heading Into J.P. Morgan
Pfizer, Sanofi, Bristol Myers Squibb, Gilead’s Kite, Lilly’s Dermira, Janssen and Biogen among the major companies announcing transactions this week.
Roivant Alliance Takes SK Into Cancer, Intractable Diseases
Korea's SK Group expands its biopharma business via a sizable investment in Roivant's protein degradation platform, through which the partners aim to progress candidates in cancer, immunology and neurology, with the first entering the clinic next year.
Asia Deal Watch: China Grand, ETheRNA Create mRNA Vaccine JV
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.